National Health Act 1953 Amendment Special Arrangements under subsection 100(1) Highly Specialised Drugs Program (No. PB 24 of 2009) (Cth)

COMMONWEALTH OF AUSTRALIA

Instrument number PB 24 of 2009

Amendment special arrangements under subsection 100(1) of the National Health Act 1953

I, DIANA MACDONELL, Acting Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsection 100(1) of the National Health Act 1953.

Dated     3rd March   2009

DIANA MACDONELL

Acting Assistant Secretary

Pharmaceutical Evaluation Branch

Department of Health and Ageing

Amendment Special Arrangements — Highly Specialised Drugs Program

1              Commencement

This instrument commences on 1 April 2009.

2              Amendment of PB 120 of 2008

Schedule 1 amends PB 120 of 2008.

Schedule 1        Amendments

1. Schedule 1, item dealing with Filgrastim

omit from the column headed “Circumstances”:

A patient receiving first-line chemotherapy for B-cell chronic lymphocytic leukaemia

and substitute:

A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia

1. Schedule 1, item dealing with Infliximab

(a) omit from the column headed “Circumstances”under the heading “Psoriatic arthritis” (first occurring):

(4) have had the psoriatic component of their disease confirmed by a dermatologist or by biopsy at any time; and

(b) re-number the next paragraph (5) as (4)

1. Schedule 1, item dealing with Pegfilgrastim

omit from the column headed “Circumstances”:

A patient receiving first-line chemotherapy for B-cell chronic lymphocytic leukaemia

and substitute:

A patient receiving chemotherapy for B-cell chronic lymphocytic leukaemia